NFX Nuformix plc

0.0009USD0.0650 GBp · LSE0.00%Mkt Cap: 2.23M USDP/E: —

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The compan…

Key Statistics

Company
Market Cap2.23M USD
Enterprise Value1.01M USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-859.35K USD
Revenue/Share—
Last Price0.0009 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees3
CountryGB
SectorHealthcare
IndustryBiotechnology
ISINGB00BYW79Y38
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-1.27
EV/Revenue—
P/S—
P/B0.65
EPS (TTM)0.00 USD
EPS (Forward)—
52W Range
0.00081% of range0.0053
52W High0.0053 USD
52W Low0.0008 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-86.44%
ROA-64.05%
ROIC—
ROCE-87.50%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-809.35K USD
CapEx (TTM)—
FCF Margin—
FCF Yield-23.02%
Net Debt-1.23M USD
Net Debt/EBITDA1.55
Net Debt/FCF—
Balance Sheet
Debt/Equity—
Current Ratio4.32
Quick Ratio4.32
Book Value/Sh0.0013 USD
Cash/Share0.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.61B
Float2.50B
Insiders5.37%
Institutions0.07%
Technical
SMA 500.0016 (-47.6%)
SMA 2000.0022 (-61.6%)
Beta1.72
S&P 52W Chg12.08%
Avg Vol (30d)22.64M
Avg Vol (10d)26.09M
Technical Indicators
RSI (14)18.4
MACD-0.0133
MACD Signal-0.0104
MACD Hist.-0.0029
BB Upper0.0016 USD
BB Middle0.0012 USD
BB Lower0.0009 USD
BB Width61.97%
ATR (14)0.0002 USD
Vol Ratio (20d)0.11x

About Nuformix (LON: NFX)

›

Nuformix (LON: NFX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 3 employees.

The shares were at 0.0650 GBp on 19 November 2026, down 76.8% over 52 weeks. Its 52-week range is 0.0600 GBp to 0.4000 GBp: the price is 83.8% below the high and 8.3% above the low.

Its market capitalisation is 1.70M GBP.

Nuformix reports return on equity of -86.4% and an operating margin of 0.0%.

It holds more cash than debt, a net cash position of 930.28K GBP. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.